Conditions: Neoplasms, Breast
Keywords: Stage IV breast cancer Herceptin metastatic breast cancer ErbB1 ErbB2 trastuzumab lapatinib
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 62
Healthy volunteers: no

Brief summary:
This study (EGF104911) is designed to evaluate the efficacy and safety of lapatinib in patients with advanced or metastatic breast cancer. Eligible subjects must have ErbB2 overexpressing tumors and are refractory to treatment with anthracycline, taxanes and trastuzumab containing regimens. The study data obtained from EGF104911 will be combined with the data from EGF100642 and integrated analysis will be carried out in order to enhance the credibility of the study results.

Detailed description:

Arms:
arm 1: Lapatinib 1500mg QD

Interventions: intervention 1: lapatinib
Intervention descriptions: intervention 1: Lapatinib 1500mg QD

Protocol document: